Navigation Links
FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder
Date:4/22/2013

irst-in-class chemical entities that boost the generation of new neurons. NSI-189, the first of these to be in a clinical trial, significantly stimulates the generation of new hippocampal neurons (neurogenesis) in vitro and in animal models.

NSI-189 is the lead compound in Neuralstem's neurogenic small molecule drug platform, which the company plans to develop into orally administered drugs for MDD and other psychiatric and cognitive disorders as diverse as traumatic brain injury, Alzheimer's disease, and PTSD. 

NSI-189 has been shown to stimulate neurogenesis of human hippocampus-derived neural stem cells in-vitro and in vivo. In healthy normal adult mice, NSI-189 stimulated neurogenesis in the hippocampus and significantly increased its volume, apparently by increasing its synaptic network after 28 days of daily oral administration. In mouse models of depression, NSI-189 significantly improved behavioral responses associated with depression. In humans, NSI-189 may reverse the human hippocampal atrophy seen in MDD and other disorders and reverse their symptoms. This program has received significant support from both the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH).

About the Trial

The NSI-189/MDD trial is a randomized, double-blind, placebo-controlled, multiple-dose escalating trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamic effect of NSI-189 in the treatment of MDD. Phase Ia, which  was completed in October 2011, tested escalating doses of single administration of NSI-189 in 41 healthy patients. Phase Ib is testing the safety of escalating doses of NSI-189 for 28 daily administrations in 24 depressed patients in three cohorts. This phase of the trial is expected to conclude in the third quarter of 2013.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
2. FDA Approves NDA Supported By MedAvante Central Ratings
3. Cardinal Health Board Of Directors Approves Cash Dividend; Authorizes New $750 Million Share Repurchase Program
4. Neuralstem Updates ALS Stem Cell Trial Progress
5. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
6. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
7. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
8. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
9. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
10. Neuralstem Announces Proposed Public Offering
11. Neuralstem to Raise $7.0 Million in Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  ResMed ... has signed a definitive agreement to acquire ... non-invasive ventilation and sleep-disordered breathing medical devices ... innovation and market reputation in China, combined with ResMed,s global leadership in sleep ... in China suffering ...
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... 2015  Unichem Pharmaceuticals ( USA ), ... tablets 25 mg 1000-count bottle to the consumer level. ... due to the identification of a Clopidogrel tablet found ... The risk associated with mistakenly taking a Clopidogrel tablet ... of experiencing Clopidogrel,s side effects which include bleeding and/or ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
... BRISBANE, Australia, Oct. 3, 2011 Ventus Medical ... Sleep Apnea Therapy, an innovative, non-invasive treatment for ... Australia and New Zealand. BMedical Pty. Ltd. will ... in these countries. (Photo:   http://photos.prnewswire.com/prnh/20110209/SF45785-a ...
... Oct. 3, 2011 PAREXEL International Corporation (NASDAQ: ... of Fiscal Year 2012 on Monday, October 31, 2011 after ... available on PAREXEL,s website at www.PAREXEL.com and on ... PAREXEL will host a conference call and live webcast at ...
Cached Medicine Technology:Ventus Medical Launches Provent® Sleep Apnea Therapy in Australia and New Zealand 2Ventus Medical Launches Provent® Sleep Apnea Therapy in Australia and New Zealand 3PAREXEL Announces Date of First Quarter Fiscal Year 2012 Earnings Release and Conference Call 2
(Date:7/30/2015)... ... July 30, 2015 , ... OSF Healthcare System has been ... Most Wired Survey conducted by Hospitals & Health Networks. This marks the fourth consecutive ... by The Sisters of the Third Order of St. Francis . , Health ...
(Date:7/30/2015)... ... 2015 , ... Women's dating coach Simone Myers has just ... interested in improving their love lives using specific "lines" designed to trigger powerful ... public early this morning, has drawn praise from several dating and relationship advice ...
(Date:7/30/2015)... ... July 30, 2015 , ... Eyepartner is ... victims in San Diego, California’s Gaslamp Quarter Plaza for five years this September. ... actively monitor the area for any suspicious activity. These cameras are in place ...
(Date:7/30/2015)... ... , ... Google recently announced that it will be disclosing any incidents involving ... June 8, 2015 article published by Nasdaq , the powerful tech company maintains ... computer-driven cars, which such industry players as Tesla CEO Elon Musk believe may very ...
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care ... Angeles, and San Bernardino counties, today announced that Dr. Michael Demoratz, PhD, LCSW, ... Demoratz is a strong proponent of early access to palliative care services for ...
Breaking Medicine News(10 mins):Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3
... ... sector. , ... Alberta (PRWEB) March 5, 2010 -- ANT Wireless ("ANT" www.thisisant.com ), a division ... A noted leader in the design and manufacturing of sport precision instruments, ...
... ... of Nevada, a Las Vegas-based healthcare organization, announced the acquisition of Rainbow Medical Center, an ... Rainbow Medical Center is now part of the Fremont Medical Centers Division of HealthCare Partners ... (PRWEB) March ...
... ... leading cause of mortality in the U.S., according to the Centers for Disease Control ... Charleston, ... problem. The culprit…Hospital Acquired Infections (HAIs) and they have generated much attention over the ...
... Mt. Everest Summiter (with ... race across the Sahara desert this April 2010. Gary is doing this to raise awareness and ... ... miles (in sections approximate to 25, 34, 38, 82, 42, 22 km) run over 6 days ...
... during the 39th Annual Meeting of the American ... E. Washington Convention Center in Washington, DC, lead ... present a poster of a study titled "TLR2 ... Reactivation." Although oral co-infections (e.g. periodontal disease) are ...
... ... the safety of the company,s products are taken very seriously. , , ... Bloomingdale, IL (PRWEB) March 4, 2010 -- ... to lead healthier lives. Product safety and quality are the company,s highest priorities; therefore any ...
Cached Medicine News:Health News:Suunto Joins ANT+ Interoperable Ecosystem 2Health News:Suunto Joins ANT+ Interoperable Ecosystem 3Health News:HealthCare Partners of Nevada and Rainbow Medical Center Join Forces 2Health News:24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination 2Health News:24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination 3Health News:Mt. Everest Summiter Gary Guller (With One Arm) To Race Across Sahara in "The World's Toughest Stage Race" 2Health News:Mt. Everest Summiter Gary Guller (With One Arm) To Race Across Sahara in "The World's Toughest Stage Race" 3Health News:Periodontal pathogens enhance HIV-1 promoter activation in T cells 2Health News:NOW Foods Response to Fish Oil and PCB Concerns 2
Rapid latex agglutination test for presumptive identification of E. coli serogroup O157:H7 isolates. Colorimetric with red O157 latex and blue H7 latex....
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
... The innovative E.coli ... Pro-Lab offers definitive identification ... the use of a ... the possibility of cross-reactions ...
... The Directigen™ Meningitis Individual Tests ... tests for the direct qualitative ... influenzae type b, S. pneumoniae, ... Escherichia coli K1 in cerebrospinal ...
Medicine Products: